1 |
Shin, J.-Y. and Choi, S.-E. : The volume and the price of generic drug consumption in Korean prescription drug market. The Korean Journal of Health Economics and Policy. 14, 103 (2008).
|
2 |
Lee, I.-H. : Evaluating pharmaceutical policy in South Korea. Health Sciences. York, University of York (2010).
|
3 |
Park, S., Jang, Y.-S., Chae, S.-M., Park, E.-J., Kim, N.-S., Lee, E. K. and Lee, I.-H. : An indepth study of the utilization and costs of pharmaceuticals in South Korea, 2010]. Seoul, Ministry of Health & Welfare, Korea Institute for Health and Social Affairs (2011).
|
4 |
Park, S., Jang, Y.-S., Chae, S.-M., Park, E.-J., Lee, E. K. and Lee, I.-H. : An indepth study of the utilization and costs of pharmaceuticals in South Korea, 2011. Seoul, Ministry of Health & Welfare, Korea Institute for Health and Social Affairs (2012).
|
5 |
Bulfone, L. : High prices for generics in Australia- more competition might help. Australian Health Review 33, 200 (2009).
DOI
|
6 |
Schweitzer, S. O. : The worldwide market for pharmaceuticals. Pharmaceutical economics and policy. 2nd ed. Oxford University Press. New York. p. 157 (2007).
|
7 |
Vogel, R. J. : Sales and marketing expenditures. Pharmaceutical economics and public policy. Pharmaceutical Products Press. New York. p. 147 (2007).
|
8 |
Cassels, A. and Lexchin, J. : Potential savings from therapeutic substitution of 10 of Canada's most dispensed prescription drugs. In: Temple NJ, Thompson A, eds. Radcliffe Publishing Ltd. Norfolk. p. 80 (2007).
|
9 |
Health Insurance Review & Assessment Service: Comprehensive quality report of National Health Insurance 2009. Seoul, Health Insurance Review & Assessment Service (2010).
|
10 |
Simoens, S. and De Coster, S. : Sustaining generic medicines markets in Europe. Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven (2006).
|
11 |
Vogler, S., Zimmermann, N., Leopold, C. and de Joncheere, K. : Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev. 4, 69 (2011).
|
12 |
Rhee, J. and Shin, G. : Factors associated with fixed budgets for pharmaceuticals in European Countries. Yakhak Hoeji 57, 213 (2013).
|
13 |
OECD : Health at a glance 2011: OECD indicators. OECD Publishing (2011).
|
14 |
Jang, S., Park, C.-M., Bae, G., Lee, H.-J. and Kim, H.-S. : Determinants of publicly funded drug expenditure in South Korea. Seoul, Health Insurance Review & Assessment Service (2011).
|
15 |
Kim, S.-O. : Realities in expensive drug prescribing and its determinants. Health Insurance Forum. 4, 57 (2005).
|
16 |
Yoon, H.-S. : National Insurance reimbursement pricing scheme: challenges and a strategy for improvement. Seoul, Korea Development Institute (2008).
|
17 |
Lee, T.-L., Hsuan, C.-F., Chang, H.-L., Wu, G. H.-M., Tseng, W.-K. and Wu, C.-C. : Is it cost-effective to change brand-name to generic simvastatin in Taiwan? Acta Cardiologica Sinica. 24, 191 (2008).
|
18 |
Kanavos, P. : Do generics offer significant savings to the UK National Health Service? Current Medical Research & Opinion. 23, 105 (2007).
DOI
ScienceOn
|
19 |
Chen, A. Y. and Wu, S. : Dispensing pattern of generic and brand-name drugs in children. Ambulatory Pediatrics. 8, 189 (2008).
DOI
ScienceOn
|
20 |
Fischer, M. A. and Avorn, J. : Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Services Research 38, 1051 (2003).
DOI
|
21 |
Jacobzone, S. : Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Paris, Organisation for Economic Co-operation and Development (2000).
|
22 |
Morgan, S. G., Bassett, K. L., Wright, J. M., Evans, R. G., Barer, M. L., Caetano, P. A. and Black, C. D. : "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ 331, 815 (2005).
DOI
|
23 |
Huh, S.-I., Jung, J.-C. and Lee, H.-Y. : A strategy for rationalising pharmaceutical expenditure. Seoul, National Health Insurance Corporation (2006).
|
24 |
You, M.-Y. : A study on the market-share of original drugs since first generic entry. Graduate School of Public Health. Seoul, Yonsei University (2007).
|
25 |
National Economic Research Associates: Policy relating to generic medicines in the OECD. London, European Commission, National Economic Research Associates (1998).
|